Profile data is unavailable for this security.
About the company
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
- Revenue in CHF (TTM)0.00
- Net income in CHF-19.62m
- Incorporated1996
- Employees50.00
- LocationSpexis AGHegenheimermattweg 125ALLSCHWIL 4123SwitzerlandCHE
- Phone+41 615671600
- Fax+41 615671601
- Websitehttps://spexisbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRISM' Therapeutics Corp | 0.00 | -395.70k | 3.51m | 4.00 | -- | 1.50 | -- | -- | -0.0408 | -0.0408 | 0.00 | 0.0634 | 0.00 | -- | -- | 0.00 | -8.18 | -8.91 | -12.38 | -9.27 | -- | -- | -- | -- | -- | -1.01 | 0.00 | -- | -- | -- | 9.04 | -- | -- | -- |
| QUIA PHARMA AB (publ) | 191.01k | -1.12m | 3.52m | 8.00 | -- | 1.25 | -- | 18.44 | -2.02 | -2.02 | 0.0119 | 0.0233 | 0.0703 | -- | 21.36 | -- | -41.30 | -95.67 | -50.35 | -207.86 | 160.51 | 262.59 | -587.29 | -5,002.50 | -- | -46.79 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| CYANOTECH CORP | 20.86m | -4.47m | 3.63m | 77.00 | -- | 0.3878 | -- | 0.1738 | -0.7549 | -0.7549 | 3.56 | 1.53 | 0.8895 | 2.05 | 12.12 | 309,389.60 | -19.04 | -3.46 | -29.60 | -4.46 | 24.72 | 34.54 | -21.41 | -3.58 | 0.3354 | -6.61 | 0.377 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
| Evoke Pharma Inc | 6.59m | -5.72m | 3.64m | 4.00 | -- | 1.56 | -- | 0.5517 | -16.23 | -16.23 | 11.24 | 3.63 | 0.7128 | 0.4307 | 4.97 | 1,881,428.00 | -61.83 | -100.48 | -136.53 | -151.10 | 96.97 | -- | -86.75 | -480.52 | 1.22 | -19.91 | 0.6523 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Tian'an Pharmaceutical Co Ltd | 9.33m | 2.75m | 3.64m | -- | 0.0232 | 0.005 | 1.14 | 0.3906 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Odi Pharma AB (publ) | 1.82m | 28.81k | 3.70m | -- | 128.26 | 20.59 | 127.22 | 2.03 | 0.0234 | 0.0234 | 1.47 | 0.1457 | 2.19 | 54.42 | 5.47 | -- | 3.48 | -35.08 | 14.86 | -44.27 | 2.07 | -- | 1.59 | -99.25 | 1.22 | 1.81 | -- | -- | 15,995.75 | -- | 105.16 | -- | -- | -- |
| Spexis AG | 0.00 | -19.62m | 3.86m | 50.00 | -- | -- | -- | -- | -0.3597 | -0.3597 | 0.00 | -0.0546 | 0.00 | -- | -- | 0.00 | -84.79 | -53.28 | -149.58 | -68.93 | -- | -- | -- | -1,117.43 | -- | -- | 1.69 | -- | -- | -- | -5.75 | -- | -- | -- |
| Jupiter Bioscience Ltd | -1.04bn | -1.04bn | 3.86m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.42 | -- | 5.61 | -- | 61.37 | -- | 17.32 | -- | -- | -- | 10.48 | 42.43 | 29.30 | 20.92 | 22.82 | 55.40 | -16.74 |
| Arctic Bioscience AS | 2.50m | -3.85m | 3.98m | 20.00 | -- | 0.2126 | -- | 1.59 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Epsilon Healthcare Ltd | 4.16m | -3.42m | 4.16m | -- | -- | 0.7868 | -- | 0.9994 | -0.0198 | -0.0198 | 0.0241 | 0.0305 | 0.3839 | 17.94 | 2.73 | -- | -31.54 | -35.68 | -46.30 | -41.11 | 37.99 | 26.88 | -82.17 | -197.56 | 0.5237 | -9.28 | 0.2329 | -- | 29.36 | 30.99 | -43.77 | -- | 8.14 | -- |
| Biofrontera Inc | 30.86m | -11.83m | 4.16m | 85.00 | -- | 0.3997 | -- | 0.1347 | -5.29 | -5.29 | 12.12 | 2.14 | 1.21 | 1.97 | 7.27 | 414,623.50 | -46.20 | -- | -113.24 | -- | 47.75 | -- | -38.33 | -- | 1.46 | -3.53 | 0.0264 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 26 Sep 2024 | 526.32k | 0.78% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 77.22k | 0.11% |
| Credit Suisse AGas of 30 Aug 2024 | 25.45k | 0.04% |
| BlackRock Asset Management Schweiz AGas of 03 Oct 2024 | 18.25k | 0.03% |
| Pictet Asset Management SAas of 30 Jun 2024 | 17.82k | 0.03% |
| LLB Asset Management AGas of 30 Jun 2024 | 2.35k | 0.00% |
| BlackRock Advisors (UK) Ltd.as of 31 Jul 2023 | 1.56k | 0.00% |
| Carne Global Fund Managers (Schweiz) AGas of 31 Oct 2024 | 1.50k | 0.00% |
| Banque Cantonale Vaudoise (Investment Management)as of 30 Jun 2024 | 0.00 | 0.00% |
